Analyst Thursdays: Benjamin Burnett discusses names and topics on Stifel's 2024 'Key Controversies List'
Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution Medicines, Fate, CRISPR Therapeutics, and Disc Medicine.
Comments